Enlicitide: The First ORAL PCSK9 Inhibitor for Cholesterol

September 2026

You’ll hear that enlicitide (Lipfendra) is a game changer for managing high cholesterol...as the first ORAL PCSK9 inhibitor.

Enlicitide 20 mg once daily lowers LDL-C by about 60% when added to a statin in adults with high cholesterol...with or without ASCVD.

This is similar to injectable PCSK9 inhibitors (alirocumab, etc).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote